Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications
Cancer Biomarkers · 2023
DOI: 10.3233/cbm-220041 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Biomarkers, 2023. Verfasst von Antonio Dono und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. Hauptthemen laut MEDLINE: Glioma, Glioblastoma, Astrocytoma, Brain Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Fibroblast growth factor receptors (FGFRs) are frequently altered in cancers and present a potential therapeutic avenue. However, the type and prevalence of FGFR alterations in infiltrating gliomas (IGs) needs further investigation. OBJECTIVE: To understand the prevalence/type of FGFR alterations in IGs. METHODS: We reviewed clinicopathologic and genomic alterations of FGFR-mutant gliomas in a cohort of 387 patients. Tumors were examined by DNA next-generation sequencing for somatic mutations with a panel interrogating 205-genes. For comparison, cBioPortal databases were queried to identify FGFR-altered IGs. RESULTS: Fourteen patients (3.6%) with FGFR-mutant tumors were identified including 11 glioblastomas, Isocitrate dehydrogenase (IDH) – wildtype (GBM-IDH-WT), 2 oligodendrogliomas, and 1 astrocytoma IDH-mutant. FGFR-altered IGs showed endocrinoid capillaries, microvascular proliferation, necrosis, oligodendroglioma-like cells, fibrin thrombi, microcalcifications, and nodular growth. FGFR3 was the most commonly altered FGFR gene (64.3%). The most common additional mutations in FGFR-altered IGs were TERTp, CDKN2A/B, PTEN, CDK4, MDM2, and TP53. FGFR3 alterations were only observed in GBM-IDH-WT. EGFR alterations were rarely identified in FGFR3-altered gliomas. CONCLUSIONS: Histologic features correlate with FGFR alterations in IGs. FGFR3-TACC3 fusion and FGFR3 amplification are the most common FGFR alterations in IGs. FGFR alterations are a rare, but potentially viable, therapeutic target in asubset of IGs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
- Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
- Rice University, Houston, TX, USA.
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Memorial Hermann Hospital-TMC, Houston, TX, USA.
- Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Zitieren
APA
Dono, A., El Achi, H., Bundrant, B. E., Goli, P. S., Zhu, P., Ozkizilkaya, H. I., Esquenazi, Y., & Ballester, L. Y. (2023). Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications. Cancer Biomarkers. https://doi.org/10.3233/cbm-220041
Vancouver
Dono A, El Achi H, Bundrant BE, Goli PS, Zhu P, Ozkizilkaya HI, et al. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications. Cancer Biomarkers. 2023. doi:10.3233/cbm-220041
BibTeX
@article{Dono2023,
author = {Dono, Antonio and El Achi, Hanadi and Bundrant, Bethany E and Goli, Puneetha S and Zhu, Ping and Ozkizilkaya, Hanim I and Esquenazi, Yoshua and Ballester, Leomar Y},
title = {Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications},
journal = {Cancer Biomarkers},
year = {2023},
doi = {10.3233/cbm-220041}
}
EUVIMED